Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

Leadership Appointments - Crescent Biopharma, Inc. announced key leadership appointments including Joshua Brumm as CEO, Jonathan McNeill, M.D. as President and COO, Ellie Im, M.D. as Chief Medical Officer, Rick Scalzo, MBA as Chief Financial Officer, and Amy Reilly as Chief Communications Officer [2][4][10][12][14] - The new leadership team brings extensive experience in oncology drug development, clinical operations, and building biotechnology companies [2][4] Company Strategy and Pipeline - Crescent is focused on developing novel precision-engineered molecules targeting solid tumors, with its lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody, on track for IND submission in Q4 2025 [2][7][15] - The company is also advancing a pipeline of novel antibody-drug conjugates (ADCs), including CR-002 and CR-003, with an IND submission for CR-002 anticipated in mid-2026 [7][15] Market Position and Vision - The leadership team aims to transform the standard of care in the immuno-oncology market, positioning Crescent to rapidly advance potentially best-in-class therapeutics across solid tumor indications [4][15] - The company is set to benefit from the collective experience of its leadership in corporate strategy, capital formation, and stakeholder engagement to progress its programs [4][10][12] Recent Developments - In October 2024, Crescent entered into an acquisition agreement with GlycoMimetics, Inc., with the combined company expected to operate under the name Crescent Biopharma and enhance its portfolio of precision-engineered biologics [7] - Initial clinical data from a Phase 1 trial for CR-001 is expected in the second half of 2026 [7]